LOGIN  |  REGISTER

Orthofix Medical to Participate in Upcoming Investor Conferences

November 12, 2024 | Last Trade: US$11.25 0.03 -0.27

LEWISVILLE, Texas / Nov 12, 2024 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences:

  • Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Eastern Time
  • Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach, CA, December 9, 2024, fireside chat at 8:00 AM Pacific Time

Live webcasts and replays, when available, can be found under "Events & Presentations" in the Investors section of the Orthofix website at https://ir.orthofix.com/events-and-presentations/.

About Orthofix

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ navigation system. To learn more, visit Orthofix.com and follow on LinkedIn.

C4 Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page